Previous 10 | Next 10 |
SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings wil...
SALT LAKE CITY, April 26, 2022 (GLOBE NEWSWIRE) -- Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental health, according to the GeneSight ® Mental Health Monitor, a new nationwide survey fr...
The U.S. FDA is warning that non-invasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when in actuality the fetus was healthy. The agency noted that these tests, which are also known as noninvasive prenatal tests (NIPT), ha...
Glenview Capital Management’s 13F portfolio value decreased from $5.46B to $4.69B this quarter. The number of positions decreased from 59 to 57. They increased Global Payments and Coca Cola Euro Partners while dropping Paramount Global and Takeda. The top three stakes are T...
SALT LAKE CITY, March 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and ...
SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the U.S. Food and Drug Administration (FDA) has approved Myriad’s BRACAnalysis ® CDx test for use as a companion...
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and preci...
SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42 nd Annual Cowen Health Care Conference on March 8, 202...
Myriad Genetics, Inc. (MYGN) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Nathan Smith - Senior Vice President of Investor Relations & Treasury Paul Diaz - President & Chief Executive Officer Nicole Lambert - Chief Operating Officer Bryan Riggsbee -...
Myriad Genetics press release (NASDAQ:MYGN): Q4 Non-GAAP EPS of -$0.02 beats by $0.04. Revenue of $160.8M (+19.0% Y/Y) misses by $1.41M. Cash, cash equivalents and investments of $398.8M Guidance FY22: The company expects the revenue to be in the range of $670M -$700M vs consensus of $6...
News, Short Squeeze, Breakout and More Instantly...
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy 1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, a...
2024-05-12 19:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...